Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Orphazyme A/S. (2/7/20). "Press Release: Orphazyme Completes Offering of 7,032,937 Shares in a Directed Issue and Private Placement and Raises approximately DKK 745,000,000 (EUR 100 Million / USD 110 Million) [Not for US, CA, JP or AU]". Copenhagen.

Organisations Organisation Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO)
  Group Orphazyme (Group)
  Organisation 2 Novo Holdings A/S
  Group Novo Group (Group)
Products Product arimoclomol
  Product 2 investment banking
Index term Index term Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares
Persons Person Stratton, Kim (Orphazyme 202002 CEO)
  Person 2 Vadsholt, Anders (TopoTarget 201011 CFO)
     


   
Record changed: 2020-02-12

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Orphazyme (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px




» top